‹ ›
MYP_107997
← PREVIOUS NEXT → BACK
Basic Information
MBD-4 (11-40) (P9 [H21R,K23R,K28R], P9R)
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-Influenza virus ▸ Anti-Influenza A ▸ Anti-Influenza A virus
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral replication inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
30 amino acids
C144H232N52O35S5
Standard
Sequence
NGAICWGPCPTAFRQIGNCGRFRVRCCRIR
Physicochemical Analysis
3412.03 Da
10.46
5.71
5.43
0.1903
-0.15
0.74
-0.15
12.80
55.33
0.1000
5500.00
5750.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1426.33
-16.34
57.0
46.0
107.0
236.0
6.0
32.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0184198 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
branched peptide architecture [Branched]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Entry inhibition
SARS-CoV-2
0.08792 μM
IC50
Mammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h
PaperCross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. | Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY. | Nat Commun. 2021 Mar 9;12(1):1517. | DOI:10.1038/s41467-021-21825-w | PMID:33750821 PMID33750821 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33750821/
RECORD: Rec_0196239 VERIFIED: YES
Provenance & Taxonomy
Mus musculus [Animal]
Defensin-derived peptide
10090
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus
2.2 μg/mL
IC50
PaperA broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2 PMID32843628 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32843628/
RECORD: Rec_0199305 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Virus
PMID32843628 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32843628/
RECORD: Rec_0199779 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Defensin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Human rhinovirus (HRV)
PMID32843628 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32843628/
RECORD: Rec_0205345 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Replication inhibition
Human parainfluenza virus 3 | LLC-MK2 cells
25 μg/mL
IC50
Mammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h
PaperA broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. | Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY. | Nat Commun. 2020 Aug 25;11(1):4252. | DOI:10.1038/s41467-020-17986-9 | PMID:32843628 PMID32843628 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32843628/
FIRST PREV 1 2 3 4 5 6 ... 8 NEXT LAST
Showing 5 records on this page · Page 4 of 8